MedTrace Logo

Phase 2, Safety & Microbiology Study of C16G2 in Multiple Oral Gel &/or Mouth Rinse Doses to Healthy Adults

NCT02044081 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2019-08-01

No results posted yet for this study

Summary

The focus of the study is to evaluate the safety of multiple study drug administrations and the study drug selectively reducing or eliminating a specific bacteria in the mouth. It will compare a liquid and gel product applied in different modes.

Conditions

  • Dental Caries

Interventions

DRUG

C16G2 Rinse

Active rinses are 1.6 mg/mL C16G2.

DRUG

Placebo

Placebo is the vehicle without C16G2

DRUG

C16G2 Gel

Active C16G2 Gel is 3.2 mg/mL

Sponsors & Collaborators

  • Armata Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • Adam Marberger, DDS · Jean Brown Research

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-02-28
Primary Completion
2014-07-31
Completion
2014-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02044081 on ClinicalTrials.gov